In this issue:
AXIOMATIC-TKR demonstrates the antithrombotic efficacy of milvexian
Liver-directed AAV gene therapy may be curative for haemophilia A
Full-dose heparin optimal for severe COVID-19 thromboprophylaxis
Fixed-dose three-factor PCC is safe and effective for warfarin reversal
High risk of MACE in survivors of iTTP
Real-world Australian report suggests low-dose rituximab-based regimen effective for AHA
Predictive significance of anti-FVIII Ig patterns on phenotype and outcomes in AHA
The contact activation inhibitor AB023 in heparin-free haemodialysis
Plasma C5 associated with risk of future VTE
Platelet EVs have a proteasome and play a role in adaptive immunity
Please login below to download this issue (PDF)